Mirxes
觅瑞
Mirxes is a Singapore-based RNA technology company focused on cancer early screening, founded by CEO Lihan Zhou . It raised a $50 million Series D in July 2023 backed by EDBI, A*STAR, Mitsui & Co., and NuoHui Venture Fund , with Gaorong Ventures as its earliest institutional investor since a 2018 Series B . The company is best known for GASTROClear™, which it describes as the world's only approved blood-based molecular test for gastric cancer early screening . Mirxes listed on the Hong Kong Stock Exchange's Main Board in 2025 .
AI-generated — may contain errors, please verify.
Coverage
Chinese online marketplace operator "Quantgroup" successfully listed on the Hong Kong Stock Exchange, with Gaorong Ventures as a co-lead investor in its Series A round.
Facilitating precise matching between consumer demand and industrial supply.
Decoding New Policies and Market Signals: How Tech and Healthcare Innovators Can Tap the Hong Kong Stock Market | Ronghui
Back to fundamentals, building differentiation.
Brain-Computer Interfaces, XR Chips Close Funding Rounds as New Products and Markets Open Fresh Chapters | Rongbao · October
Embrace the new era of growth.
Multiple Innovative Companies Gain Global Recognition, Breakthroughs Achieved in Computational Biology, LiDAR, and Other Fields | Rongbao · July
Major events in July.
Chips, Energy Storage, and LiDAR Accelerate Commercialization; Robotics and SaaS Expand Globally | Rongbao · May
Sailing through the waves, striving upstream.
"Tiny but Mighty" miRNA: How Cancer Can Be Caught at Its Earliest Stage | Gaorong Ventures "Future"
By applying microRNA to early cancer screening, we can transform cancer from a terminal illness into a chronic disease that can be intercepted at an early stage.
Gaorong Monthly · October | Gaorong Ventures Named Among Zero2IPO's Top 10 VC Firms of the Year; Nuro Closes Major Series D Round
Autonomous driving, healthcare, and chip sectors see new funding rounds; Genki Forest unveils "Triple Zero Factory" strategy; Dingdong Maicai stabilizes prices and ensures supply.
Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
